|Executive Directors||Non-executive Directors||Independent Non-Executive Directors|
Mr. CHAU Wai Wah Fred
Mr. HO Kam Kin
Ms. KWOK Shuk Yi
|Dr. CHENG Yanjie||
Mr. LAU Fai Lawrence
Dr. LIU Ta-pei
Mr. LAM Kit Sun
Mr. CHAU Wai Wah Fred, aged 60, is an executive director, authorised representative and compliance officer of the Company. He is also a member of the remuneration committee and nomination committee of the Company and was an independent non-executive director and a member of the audit committee of the Company. He is the director of various subsidiaries of the Group. He joined the Group in November 2019. He was formerly the Head of the Office of Dutiable Commodities Administration of Hong Kong Customs and Excise Department (C&ED) and retired with rank of Senior Superintendent. He has served the C&ED for 34 years with wide range of exposure including intellectual property rights (IPR) protection, anti-smuggling, anti-narcotics, intelligence and liaisons and dutiable commodities administration. Mr. Chau has served as the Divisional Commander and Group Head of the Intellectual Property Investigation Bureau to combat on organized transnational crimes, in particular in IPR infringement cases with the Mainland and overseas counterparts. Mr. Chau was awarded the honours of Customs and Excise Medal for Meritorious Service (C.M.S.M.) by the Chief Executive in the 2017 honours presentation ceremony.
Mr. HO Kam Kin, aged 45, is an executive director, the Group chief financial officer, company secretary and authorised representative of the Company. He is also a director of a subsidiary of the Company. He is a member of the Hong Kong Institute of Certified Public Accountants and a fellow member of the Association of Chartered Certified Accountants. He obtained a Bachelor of Arts Degree in Accountancy and Master Degree of Corporate Finance from The Hong Kong Polytechnic University. Mr. HO held senior accounting positions in a number of companies listed on the Stock Exchange and worked in international audit firms for over three years. He has over 20 years of experience in financial reporting and financial management. Prior to joining the Company, he was the financial controller and company secretary of Great China Holdings (Hong Kong) Limited (Stock code: 21.HK), a company listed on the Main Board of The Stock Exchange of Hong Kong Limited. Mr. HO joined the Group in September 2016.
Ms. KWOK Shuk Yi, aged 46, is an executive director, the director of Group human resources and public relations of the Company. She holds a bachelor’s degree in Human Resources Management from The Royal Melbourne Institute of Technology University in Australia and graduated with distinction. She has over 20 years of experience in human resources management in Hong Kong listed companies, China and overseas investment companies. In the Group, in addition to being responsible for human resources and administration management, she has also expanded the management scope to business-related public relations in recent years. In the future, she will be involved more in management of the Group’s business strategies and overall operations. She joined the Group in July 2008.
Dr. CHENG Yanjie, aged 58, is a non-executive Director of the Company. Being a practicing Chinese medicine practitioner, he holds Bachelor degree of Traditional Chinese Medicine of Changchun University of Chinese Medicine (長春中醫學院中醫系學士學位), Master of Neurology of the Affiliated Hospital of Changchun University of Chinese Medicine (長春中醫學院附屬醫院神經內科碩士學位) and Doctor of Neurology of Beijing University of Chinese Medicine Dongzhimen Hospital (北京中醫藥大學東直門醫院神經內科博士學位). He previously served as Resident Neurologist of the Affiliated Hospital of Changchun University of Chinese Medicine (長春中醫學院附屬醫院神經內科住院醫師), Attending Physician of China Medical Center in Kuwait (科威特國中國醫療中心主治醫師), Neurology attending physician of Beijing University of Chinese Medicine Dongzhimen Hospital (北京中醫藥大學東直門醫院神經內科主治醫師) and worked in the R&D department of China National Pharmaceutical Group Co., Ltd. (中國藥材集團公司). He serves as committee member of China Pharmaceutical Culture Society (中國藥文化協會理事), executive director of Beijing Chaoyang District Chinese Medicine Association (北京市朝陽區中醫協會常務理事) and expert speaker of knowledge base popularization and bilingual health lecture of Beijing Chaoyang District (北京市朝陽區中醫科普及雙語養生講座專家). Dr. CHENG is currently the Chief Physician of Chinese medicine clinic of Beijing Luxiancaotang (北京鹿銜草堂中醫診所主任醫師). He currently serves as director and consultant of Sinopharm Traditional Chinese Medicine Co. Ltd (國藥藥材股份有限公司) and a director of Bencao Lihua Investment Management Co., Ltd. (本草利華投資管理有限公司). As at the date of this annual report, Sinopharm Traditional Chinese Medicine Co. Ltd wholly owned the equity interest in Sinopharm Traditional Chinese Medicine Overseas Holdings Limited which was a substantial shareholder of the Company. He held 5% of the equity interest in Bencao Lihua Investment Management Co., Ltd. (本草利華投資管理有限公司) which is one of the shareholders of Sinopharm Traditional Chinese Medicine Co. Ltd.
Mr. LAU Fai Lawrence, aged 51, is an independent non-executive Director of the Company and a chairperson of the audit committee and remuneration committee of the Company. Mr. LAU is currently a practising certified public accountant in Hong Kong and a fellow member of the Association of Chartered Certified Accountants in the United Kingdom. Mr. LAU graduated from The University of Hong Kong with a bachelor’s degree in business administration in 1994 and obtained a master’s degree in corporate finance from Hong Kong Polytechnic University in 2007. Mr. LAU is currently the company secretary of BBMG Corporation (stock code: 2009.HK) since August 2008, an executive director of Future World Financial Holdings Limited (stock code: 572.HK) since January 2014, an independent non-executive director of Artini Holdings Limited (stock code: 789.HK) since April 2008, Titan Petrochemicals Group Limited (stock code: 1192.HK) since March 2014, Renco Holdings Group Limited (stock code: 2323.HK) since March 2016 and China Energine International (Holdings) Limited since March 2020 (stock code: 1185.HK). Mr. LAU was a non-executive director of Alltronics Holdings Limited (stock code: 833.HK) between March 2017 and December 2018, an independent non- executive director of Winto Group (Holdings) Limited (stock code: 8238.HK) between April 2019 and November 2019 and Tenwow International Holdings Limited (stock code: 1219.HK) between November 2018 and November 2020.
Dr. LIU Ta-pei, aged 70, is an independent non-executive Director of the Company. He is also a member of the audit committee, the remuneration committee and the nomination committee of the Company respectively. He graduated from National Chung-Hsing University in Taiwan. After graduation, he continued his studies in National Cheng-Chi University, Taiwan and the University of Southern California, U.S.A. and obtained Master of Science and MBA degrees respectively. He was then conferred his Doctoral degree in public administration from the University of La Verne, U.S.A, and the Doctoral degree in Finance from Shanghai University of Finance and Economics. Apart from his strong educational background, Dr. LIU has been active in the financial field for more than 24 years. Dr. LIU was previously the executive director of Huisheng International Holdings Limited, which is listed on the Main Board of the Stock Exchange (Stock code: 1340.HK) from June 2016 to February 2020. He was previously the director of Mega Financial Holdings Company Limited (“Mega Financial Holdings”), which is listed on the Taiwan Stock Exchange Corporation (Stock code: 2886.TW) and also served as the chairman of Mega Securities Co., Ltd, a subsidiary of Mega Financial Holdings. He had also been the director of Global Securities Finance Corporation, Chung Hsing Bills Finance Corporation, and Central Investment Holding Company, and the chairman of Jen Hwa Investment Holding Company. Dr. LIU had served China Development Industrial Bank, one of the top management of Taiwan’s largest Investment Banks. He had also been the chief executive officer and an executive director of the Core Pacific-Yamaichi Group in Hong Kong. Dr. LIU was ranked as one of the ‘Top Ten Intelligent Financial Personnel in Greater China’ and he was conferred the ‘Best Integrity Award’ in 2008. He was also granted the honour of “Golden Peak Award of Outstanding Corporation Leaders in Taiwan” in 1998. Dr. LIU is currently a member of the Hong Kong-Taiwan Business Co-operation Committee. He joined the Group in February 2017.
Mr. LAM Kit Sun, aged 45, is an independent non-executive director of the Company, the chairperson of the nomination committee of the Company and a member of the audit committee and remuneration committee of the Company. He joined the Company in August 2022. He is an executive director, chief financial officer and company secretary of Universe Entertainment and Culture Group Company Limited (stock code: 1046), the securities of which are listed on the Main Board of The Stock Exchange of Hong Kong Limited since August 2013. He has over 20 years’ experience in the field of financial reporting, financial management and audit experience in the PRC and Hong Kong. He graduated from The Hong Kong University of Science and Technology with a bachelor’s degree in Business Administration in Accounting. Mr. LAM is a fellow and practicing member of the Hong Kong Institute of Certified Public Accountants, a fellow member of the Association of Chartered Certified Accountants, an associate of The Hong Kong Chartered Governance Institute and a non-practicing member of the Chinese Institute of Certified Public Accountants.